10 Lymphoma Clinical Trials in Cleveland, MS (2026)

Q: How do I join a clinical trial in Cleveland?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you.

Recruiting Lymphoma Studies in Cleveland

NCT06393738Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R...

Cleveland, MS255 participantsArvinas Inc.

View Study Details

NCT04970901Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the ...

Cleveland, MS200 participantsADC Therapeutics S.A.

View Study Details

NCT07123454Recruiting

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Ref...

Cleveland, MS91 participantsAstraZeneca

View Study Details

NCT07015242Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central N...

Cleveland, MS65 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06534060Recruiting

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

Cleveland, MS46 participantsMarch Biosciences Inc

View Study Details

NCT06015880Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL)...

Cleveland, MS30 participantsNational Cancer Institute (NCI)

View Study Details

NCT06175000Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

Cleveland, MS28 participantsProvidence Health & Services

View Study Details

NCT06447376Recruiting

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutan...

Cleveland, MS20 participantsTaylor Brooks

View Study Details

NCT07003295Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvem...

Cleveland, MS20 participantsNational Cancer Institute (NCI)

View Study Details

NCT05312801Recruiting

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posi...

Cleveland, MS20 participantsLuminary Therapeutics

View Study Details

About Lymphoma Clinical Trials in Cleveland

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 10 lymphoma clinical trials recruiting participants in Cleveland, MS. These studies are seeking a combined 775 participants. Research is being sponsored by Arvinas Inc., ADC Therapeutics S.A., AstraZeneca and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Cleveland — FAQ

Are there lymphoma clinical trials in Cleveland?

Yes, there are 10 lymphoma clinical trials currently recruiting in Cleveland, MS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cleveland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cleveland research site will contact you about next steps.

Are clinical trials in Cleveland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cleveland studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 10 active trials in Cleveland are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 13, 2026 from ClinicalTrials.gov